Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

被引：0
作者：
Nathan R Hill
Daniel Lasserson
Ben Thompson
Rafael Perera-Salazar
Jane Wolstenholme
Peter Bower
Thomas Blakeman
David Fitzmaurice
Paul Little
Gene Feder
Nadeem Qureshi
Maarten Taal
Jonathan Townend
Charles Ferro
Richard McManus
FD Richard Hobbs
机构：
[1] University of Oxford,Nuffield Department of Primary Care Health Sciences
[2] John Radcliffe Hospital,NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust
[3] University of Oxford,Department of Public Health
[4] University of Manchester,Centre for Primary Care, Institute of Population Health
[5] University of Birmingham,Primary Care Clinical Sciences, School of Health and Population Sciences, College of Medical and Dental Sciences
[6] University of Southampton,Primary Medical Care
[7] Aldermoor Health Centre,School of Social and Community Medicine
[8] University of Bristol,School of Medicine
[9] University Park,Department of Renal Medicine
[10] Royal Derby Hospital,Cardio
[11] Queen Elizabeth Hospital Birmingham and University of Birmingham,Renal Research Group, Departments of Cardiology and Nephrology
来源：
Trials | / 15卷 / 1期
关键词：
Cardiovascular disease; Chronic kidney disease; CKD mortality; CKD aldosterone receptor antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 290 条
[1]  
de Lusignan S(2011)Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease Nephron Clin Pract 117 c213-c224
[2]  
Tomson C(2012)UK Prevalence of chronic kidney disease for the adult population is 6.76% based on two creatinine readings [Erratum] Nephron Clin Pract 120 c107-352
[3]  
Harris K(2013)Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention Lancet 382 339-2047
[4]  
van Vlymen J(2007)Prevalence of chronic kidney disease in the United States JAMA 298 2038-470
[5]  
Gallagher H(2009)The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care Implementation Sci 4 39-188
[6]  
de Lusignan S(1999)A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 461-12
[7]  
Tomson C(2006)Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey BMJ 333 1047-663
[8]  
Harris K(2005)Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000 J Am Soc Nephrol 16 180-1305
[9]  
van Vlymen J(2003)Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 1-2081
[10]  
Gallagher H(2004)Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization Arch Intern Med 164 659-615
12345678910